NCT04945018View on ClinicalTrials.gov

A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

July 31, 2025

Study Completion Date

January 31, 2026

Conditions
Heart FailureIschemic Heart Disease
Interventions
BIOLOGICAL

HS-001 CS

Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension

DEVICE

HS-001-D needle, HS-001-D Adaptor

Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors

Trial Locations (8)

Unknown

St. Marianna University Hospital, Kawasaki

Saitama Medical University International Medical Center, Saitama

Juntendo University Hospital, Tokyo

Nihon University Itabashi Hospital, Tokyo

The University of Tokyo Hospital, Tokyo

Tokyo Medical and Dental University Medical Hospital, Tokyo

Tokyo Metropolitan Geriatric Medical Center, Tokyo

Tokyo Women's Medical University, Tokyo

Sponsors

Lead Sponsor

Heartseed Inc.
All Listed Sponsors
lead

Heartseed Inc.

INDUSTRY